Collaborate

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC

Shots: The companies collaborated to assess Turning Point’s elzovantinib (TPX-0022) in combination with EQRx’s aumolertinib in patients with EGFR mutant MET-amplified advanced NSCLC Turning Point will sponsor and conduct a P-Ib/II clinical trial to evaluate the safety, tolerability and preliminary efficacy of the combination regimen and will assume all costs associated with the trial whereas …

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC Read More »

Nestle and Seres Collaborate to Jointly Commercialize SER-109 for Recurrent Clostridioides difficile Infection

Shots: Seres to receive $175M up front, $125M upon the US FDA’s approval of SER-109 along with ~$225M as a commercial milestone. Seres will be responsible for development & pre-commercialization costs in the US and will be entitled to 50% of the commercial profits The agreement includes co-commercialization of microbiome therapeutics in the US and …

Nestle and Seres Collaborate to Jointly Commercialize SER-109 for Recurrent Clostridioides difficile Infection Read More »

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development

Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19 Microsoft will provide AI technology and applied scientists to work …

UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development Read More »

Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease

Shots: The Gates Foundation will provide funding support to discover and develop in vivo gene therapy for SCD. The alliance brings together Novartis drug discovery and gene therapy expertise with Gates’ funding’s The focus of the agreement to address the disparity in access to treatments and to prioritize populations and regions bearing the greatest burden …

Novartis Collaborates with Bill & Melinda Gates Foundation to Discover and Develop Gene Therapy for Sickle Cell Disease Read More »

Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease

Shots: The alliance will investigate the effectiveness of LPC-bound EPA/DHA in preventing cognitive decline linked to AD. Aker BioMarine will supply the research team with its krill-based LPC EPA/DHA product (Lysoveta) The team will evaluate the link between genetic variations in lipid metabolism & transport of EPA/DHA across the BBB using knock-in mice for human …

Aker BioMarine Collaborate with Université de Sherbrooke Department of Medicine for Alzheimer’s Disease Read More »

Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies

Shots: Ensoma to receive $100M in up front & preclinical research payment, $10M in equity investment, and is eligible to receive $1.25B as development and commercialization milestones along with royalties on sales of each product Takeda to get an exclusive WW rights Ensoma’s Engenious vectors for up to five rare disease indications. Ensoma to conduct …

Takeda Collaborates with Ensoma to Accelerate Next-Generation In Vivo Gene Therapies Read More »

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer

Shots: MTEM to receive $70M up front and is also eligible to receive ~$1.3B as development, regulatory and sales milestone along with royalties on future sales MTEM will be responsible for research activities to discover next generation ETBs for multiple targets, of which BMS selected the first target. BMS to get an option to obtain …

BMS Collaborate with Molecular Templates to Develop Engineered Toxin Body Therapies for Cancer Read More »

Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Shots: The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases …

Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics Read More »

Hologic Collaborate with Google Cloud to Advance Screening in Cervical Cancer

Shots: The companies collaborated to integrate Google Cloud’s ML technologies with Hologic’s Genius Digital Diagnostics System to transform screening and accelerate the eradication of cervical cancer across the globe The alliance promises to migrate the system’s data management infrastructure to the cloud, and the two companies will also work to further develop its deep learning …

Hologic Collaborate with Google Cloud to Advance Screening in Cervical Cancer Read More »

CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants

Shots: The collaboration combines expertise, resources and technology from both parties to develop and manufacture variant vaccines against SARS-CoV-2 variants. CureVac is expected to supply 50M doses of variant vaccines to the UK, following the regulatory approval The VTF and the CureVac will deploy mRNA platform to assess multiple SARS-CoV-2 variants and are expected to …

CureVac Collaborate with UK Government to Develop Vaccines Against SARS-CoV-2 variants Read More »

Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis

Shots: Imcyse to receive up front, ~$180M as milestones along with royalties. Pfizer to purchase an equity stake in Imcyse Initially, the companies will collaborate to develop existing lead candidates and further optimize potential molecules. Later, Pfizer will lead clinical development and commercialization activities for the program The Imotope platform is a curative approach to …

Pfizer Signs a License and Research Agreement with Imcyse to Develop Imotopes for Rheumatoid Arthritis Read More »

GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines

Shots: CureVac to receive $90.14M up front, $90.14M as milestones on the achievement of specific milestones. GSK will be the marketing authorization holder for the vaccine (Ex-Switzerland) and will have exclusive rights in all countries except Germany, Austria and Switzerland Additionally, GSK will support the manufacture of ~100M doses of CureVac’s first generation COVID-19 vaccine …

GSK Collaborate with CureVac to Develop Next Generation mRNA COVID-19 Vaccines Read More »

Gilead Signs an Option and License Agreement with Gritstone for HIV Vaccine

Shots: Gristone to receive $60M at closing, including $30M up front and a $30M as an equity investment at a premium and is eligible to receive up to ~$725M as option exercise payments and milestones along with royalties on sales of therapy Gilead will be in charge of conducting a P- I study for the …

Gilead Signs an Option and License Agreement with Gritstone for HIV Vaccine Read More »

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development

Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and Roche to advance the application of quantum computing to pharmaceutical …

Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development Read More »

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19

Shots: Lilly has expanded its ongoing BLAZE-4 trial to assess the administration of bamlanivimab (700mg) with VIR-7831 (500mg) for symptomatic COVID-19 in the outpatient setting. These are two neutralizing Abs that bind to different epitopes of the SARS-CoV-2 spike protein The companies reported the first patient has been dosed in the expanded study Bamlanivimab is …

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19 Read More »

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens

Shots: Cardiff University will receive milestone payments that advance from the discovery collaboration into clinical development and royalty payments on sales of any products that reach the market. Ervaxx will fund this program Ervaxx gains an exclusive license to Cardiff University patents claiming T cells and TCRs reactive to cancer-specific antigens and has the right …

Ervaxx and Cardiff University Collaborate to Develop Novel T-cell and T-cell Receptor-based Immunotherapeutics Targeting Dark Antigens Read More »

Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases

Shots: MiNA to receive $267.6M in up front, exclusivity fee on first neurological target and will be eligible to receive research, development, regulatory and commercial milestones along with royalties Servier will lead pre/ clinical development of lead candidates and will have the rights to commercialize any products that emerges from the collaboration The collaboration integrates …

Servier and MiNA Therapeutics Collaborate to Develop saRNA Therapies for Neurological Diseases Read More »

Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies

Shots: Merus to receive $40M up front, $20M as an equity investment, ~$540M as development & commercial milestones making it a total of $1.6B for three products, along with royalties, following the commercialization of therapies Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research, development, …

Lilly and Merus Collaborate to Discover Novel T-Cell Re-Directing Bispecific Antibodies Read More »

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases

Shots: The companies plan to leverage TenNor’s multitargeting drug conjugation platform to discover new therapies for NTM diseases. The agreement was facilitated by J&J The focus of the pact to discover and develop novel therapies for NTM diseases with the potential to shorten the duration of treatment with better safety and efficacy The collaboration builds …

Janssen Signs a Research Agreement with TenNor to Develop Treatments for Nontuberculous Mycobacteria Diseases Read More »

Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies

Shots: KSQ to receive $100M+ as up front and preclinical milestones and up to $400M+/ program in option payment and development & commercialization milestones along with royalties on sales of each approved products The deal includes two KSQ’s previously identified & validated T-cell targets with the potential to introduce two additional targets to the collaboration …

Takeda and KSQ Collaborate to Develop and Commercialize Novel Immuno-Oncology Therapies Read More »

Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases

Shots: Chi-Med to receive ~$95M and ~$135M as development & commercial milestones along with royalties on commercialization of each drug candidates. Inmagene to get an exclusive option for four drug candidates solely for immunological diseases If Inmagene exercises the option, it will get the right to further develop, manufacture and commercialize the specific drug candidate …

Chi-Med and Inmagene Collaborate to Develop Therapies for Immunological Diseases Read More »

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies

Shots: Tyris to receive up front, research milestone along with research funding and will be responsible for generating clinical lead candidates and will further progress them to clinical development Almirall to get an exclusive option to acquire gene therapies and progress them through clinical development to commercialization The collaboration will integrate Tyris’s non-viral based gene …

Almirall and Tyris Collaborate to Develop Next Generation Gene Therapies Read More »

Bayer to Fund Five New Startup Companies as Part of G4A Digital Health Partnerships Program

Shots: The funding focuses on fostering the development of a digital health ecosystem in the fields of cardiometabolic and renal diseases, oncology, and women’s health Bayer G4A partnership program offers 2 digital health collaboration segments. Under its Growth Track, selected early-stage startups receive $118.29M funding to accelerate market uptake and tailored business acceleration clinics and …

Bayer to Fund Five New Startup Companies as Part of G4A Digital Health Partnerships Program Read More »

Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer

Shots: Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination of zanidatamab and ALX148 in a two-part study The 1st part will evaluate the safety of the combination regimen while the 2nd part will assess the safety, tolerability, and anti-tumor activity in separate cohorts of subjects with HER2+ BC, …

Zymeworks and ALX Oncology Collaborate to Evaluate Zanidatamab + ALX148 for Advanced HER2‑Expressing Breast Cancer Read More »

Merck and Transcenta Collaborate to Implement Continuous Manufacturing for Protein Therapeutics

Shots: The companies will co-develop a first-of-its-kind, single-use flow-through polishing system for GMP operation. The collaboration expected to accelerate affordable access to therapeutics for patients in China and globally The agreement will initially focus on developing and designing the process technologies and automation while later focus on the expanded scope of the process and digital …

Merck and Transcenta Collaborate to Implement Continuous Manufacturing for Protein Therapeutics Read More »

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer

Shots: Fusion to receive up front, as well as development milestones and other payments. The companies will jointly discover, develop, and have an option to co-commercialize novel TATs in the US while AstraZeneca will lead commercialization in the ROW with equal profit & loss sharing globally The collaboration leverages Fusion’s TAT platform and expertise in …

AstraZeneca and Fusion Collaborate to Develop and Commercialize Radiopharmaceuticals and Combination Therapies for Cancer Read More »

AWS and Onica Collaborate with Teva to Support its Digihaler Portfolio

Shots: The three companies collaborated to build & host Teva’s Digital Health Platform which is a cloud-based backend data system, supporting the company’s FDA-approved Digihaler portfolio that consists of built-in sensors and Bluetooth wireless technology which connects to a mobile app that tracks inhaler events and measures inspiratory flow when a patient inhales Onica supported …

AWS and Onica Collaborate with Teva to Support its Digihaler Portfolio Read More »

AbbVie and Harvard University Collaborate to Develop Novel Therapies Against Emergent Viral Diseases

Shots: AbbVie and Harvard University enter a $30M research alliance to study & develop novel therapies against emergent viral infections with an initial focus on coronavirus and the viruses leading to hemorrhagic fever The focus of the collaboration is to integrate fundamental biology into the pre/clinical development of new therapies for viral diseases AbbVie will …

AbbVie and Harvard University Collaborate to Develop Novel Therapies Against Emergent Viral Diseases Read More »

Bayer and One Drop Collaborate to Develop Digital Therapies Across Multiple Therapeutic Areas

Shots: The two partners will jointly enhance the existing platform utilizing One Drop’s know-how and capabilities of the One Drop platform and will co-develop digital health therapies across multiple therapeutic areas                One Drop will receive $98M financing, development fees and commercial milestones while in exchange Bayer will receive royalties on sales. In the future, Bayer …

Bayer and One Drop Collaborate to Develop Digital Therapies Across Multiple Therapeutic Areas Read More »

SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine

Shots: SK bioscience signs a development and supply agreement for Novavax’ NVX-CoV2373 to supply it globally including the COVAX facility. SK bioscience will manufacture the vaccine antigen component for use in the final drug product SK bioscience will utilize its cell culture and recombinant protein capability, will initiate the production of the NVX-CoV2373 antigen at …

SK bioscience Collaborate with Novavax to Supply Antigen for COVID-19 Vaccine Read More »

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US

Shots: Alvotech will lead the development, registration, and supply of the biosimilars, while Teva will be exclusively commercializing the products in the US. Alvotech will receive upfront with subsequent milestone payments over the next several years The companies will share the profit from the commercialization of the biosimilars. The collaboration leverages Teva’s commercial presence and …

Teva and Alvotech Collaborate to Commercialize Five Biosimilar Candidates in the US Read More »

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH

Shots: Hanmi to receive $10M up front, $860M as development, regulatory approval, and commercialization of efinopegdutide along with royalties on sales of the approved product Merck to receive an exclusive license to develop, manufacture and commercialize efinopegdutide in the US and globally while Hanmi to retain an option to commercialize the therapy in Korea Efinopegdutide …

Merck and Hanmi Collaborate to Develop Efinopegdutide for NASH Read More »

Roche and UCB Collaborate to Develop UCB0107 for Alzheimer’s Disease

Shots: UCB to receive $120M and is eligible to receive $2B as cost reimbursement, development, and commercial milestones as well as royalties on sales of the therapies, if Roche proceeds the clinical development. Roche to get an exclusive license to develop and commercialize UCB0107 for AD UCB to fund and perform a POC study in …

Roche and UCB Collaborate to Develop UCB0107 for Alzheimer’s Disease Read More »

Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome

Shots: Ovid will collaborate with UConn’s Stormy J. Chamberlain and secures exclusive access to identified genetic sequences for shRNA-based therapy. Ovid plans to leverage its translational medicine capabilities and drug development expertise in Angelman syndrome to advance OV101 into clinical Ovid is developing OV101 for Angelman syndrome to restore tonic inhibition addressing several core symptoms …

Ovid Therapeutics and University of Connecticut Collaborate to Accelerate the Development of OV101 (gaboxadol) for Angelman Syndrome Read More »

Chugai and Biofourmis Collaborate to Develop Solutions for Digitally Measuring Endometriosis Pain

Shots: The collaboration will deploy Biofourmis’ Biovitals platform to co-develop a novel digital technology for the objective assessment of pain using biosensors and AI-based algorithms. The solutions will be validated in the global study that enrolls 120+ endometriosis patients The digital solution for managing patients with endometriosis in an ambulatory setting will include a wearable, …

Chugai and Biofourmis Collaborate to Develop Solutions for Digitally Measuring Endometriosis Pain Read More »